Search Results for "moderate concentrate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for moderate concentrate. Results 11 to 20 of 505 total matches.
Intravenous Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • Aug 09, 1991 (Issue 850)
Infect Dis, 163:1279, June
1991), and the drug is only moderately active against Streptococcus ...
Ciprofloxacin, previously available orally (Cipro - Medical Letter, 30:11, 1988) and for ophthalmic use (Ciloxan - Medical Letter, 33:52, May 31, 1991), is now the first fluoroquinolone antibiotic to become available in the USA in an intravenous (IV) formulation. Cipro I.V. (Miles) is being promoted as an alternative to third-generation cephalosporins, aminoglycosides, and other drugs used for treatment of serious infections.
Roflumilast Cream (Zoryve) for Atopic Dermatitis
The Medical Letter on Drugs and Therapeutics • Sep 16, 2024 (Issue 1711)
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate ...
The FDA has approved a 0.15% cream formulation
of the phosphodiesterase-4 (PDE4) inhibitor
roflumilast (Zoryve – Arcutis) for topical treatment of
mild to moderate atopic dermatitis (AD) in patients
≥6 years old. Roflumilast is the second PDE4 inhibitor
to be approved in the US for treatment of AD;
crisaborole (Eucrisa), which can be used in patients
≥3 months old, was the first. Roflumilast is available
as Zoryve in a 0.3% cream for treatment of plaque
psoriasis and a 0.3% foam for treatment of seborrheic
dermatitis. It is also available in an oral formulation
(Daliresp) for...
Med Lett Drugs Ther. 2024 Sep 16;66(1711):150-1 doi:10.58347/tml.2024.1711b | Show Introduction Hide Introduction
Topical Pimecrolimus (Elidel) for treatment of atopic dermatitis
The Medical Letter on Drugs and Therapeutics • May 27, 2002 (Issue 1131)
in 260
adults with moderate to severe atopic dermatitis involving 5-30% BSA compared four concentrations ...
Pimecrolimus 1% cream (pim e kroe' limus; SDZ ASM 981; Elidel - Novartis) has been approved by the FDA for short-term and intermittent long-term treatment of mild to moderate atopic dermatitis in non-immunocompromised patients at least 2 years old.
Betaine for Homocystinuria
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997 (Issue 993)
bottle.
HYPERHOMOCYSTINEMIA AS A RISK FACTOR FOR VASCULAR DISEASE — Moderately increased concentrations ...
Betaine (Cystadane - Orphan Medical), an orphan drug, has recently been marketed for treatment of homocystinuria, a genetic disorder. Patients with homocystinuria frequently have premature atherosclerosis and thromboembolism, and may also have lens dislocations, skeletal abnormalities and mental retardation (SH Mudd et al in CR Scriver et al, eds, The Metabolic and Molecular Bases of Inherited Disease, 7th ed, New York:McGraw Hill, 1995, page 1279).
Transdermal Buprenorphine (Butrans) for Chronic Pain
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011 (Issue 1362)
opioid agonist
buprenorphine in a transdermal formulation (Butrans –
Purdue) for treatment of moderate ...
The FDA has approved the partial opioid agonist
buprenorphine in a transdermal formulation (Butrans –
Purdue) for treatment of moderate to severe chronic
pain. Buprenorphine has been available in the US for
years in parenteral formulations for pain and in sublingual tablets for opioid dependence.1 Transdermal
buprenorphine has been available in Europe for several
years.2
A New Ace Inhibitor and Two New Angiotensin Receptor Blockers For Hypertension
The Medical Letter on Drugs and Therapeutics • Nov 05, 1999 (Issue 1065)
metabolite perindoprilat, which reaches peak serum concentrations in 3 to
7 hours and is excreted mostly ...
Perindopril, the tenth angiotensin converting enzyme (ACE) inhibitor to be marketed in the USA, and telmisartan and eprosartan, the fifth and sixth angiotensin receptor blockers, have recently become available for treatment of hypertension.
Etrasimod (Velsipity) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
of moderate or strong inhibitors or inducers of these isozymes can affect serum concentrations of etrasimod ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator etrasimod (Velsipity – Pfizer) has been
approved by the FDA for treatment of moderately to
severely active ulcerative colitis in adults. It is the
second oral S1P receptor modulator to be approved
in the US for this indication; ozanimod (Zeposia) was
the first.
Med Lett Drugs Ther. 2023 Nov 27;65(1690):187-9 doi:10.58347/tml.2023.1690b | Show Introduction Hide Introduction
Benzgalantamine (Zunveyl) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Apr 14, 2025 (Issue 1726)
, for treatment of mild to moderate
dementia of Alzheimer's disease (AD). Immediate- and
extended-release ...
The FDA has approved Zunveyl (Alpha Cognition),
a delayed-release formulation of the prodrug
benzgalantamine, for treatment of mild to moderate
dementia of Alzheimer's disease (AD). Immediate- and
extended-release formulations of the acetylcholinesterase
inhibitor galantamine have been
available in the US for years for treatment of AD.
Med Lett Drugs Ther. 2025 Apr 14;67(1726):59-60 doi:10.58347/tml.2025.1726b | Show Introduction Hide Introduction
Paroxetine (Brisdelle) for Hot Flashes
The Medical Letter on Drugs and Therapeutics • Oct 28, 2013 (Issue 1428)
(Brisdelle) for Hot Flashes reduction in the frequency of moderate-to-severe hot
flashes from baseline ...
The FDA has approved a low-dose formulation of the
selective serotonin reuptake inhibitor (SSRI) paroxetine
mesylate (Brisdelle – Noven Therapeutics) for treatment
of moderate-to-severe vasomotor symptoms associated
with menopause. It is the first non-hormonal therapy to
be approved for this indication. Paroxetine mesylate
(Pexeva) and paroxetine hydrochloride (Paxil, and
generics) are marketed in higher doses for treatment of
depression and other psychiatric disorders.
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
to moderate
uncomplicated onychomycosis ( ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.